Will Actavis Win Competition For Allergan's Affection?
Four pharmaceutical companies have been flirting with merger deals. Discussing the confusing courting, Barron’s called them the Bob & Carol & Ted & Alice of pharmaceuticals, referencing the sexy 1969 comedy-drama with the tag line “Consider the Possibilities.”
In no particular order, the companies hoping to partner up were Valeant Pharmaceuticals Intl Inc (NYSE: VRX) Allergan, Inc. (NYSE: AGN) Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) and Actavis Plc (NYSE: ACT).
Meanwhile, Actavis began pursuing Allergan. Valent continued its effort undeterred by the competition. The result: a confusing (to say the least) four-way merger ‘tryst.’ None of the flirtations been able to get a merger deal "put to bed" yet, however.
An Analyst’s Take
Adding that although it was possible Allergan could pursue an acquisition, “a far clearer path to upside for Allergan shares” would be via an acquisition of Allergan by Actavis or Valeant.
Enter Actavis (Again)
Reuters reported on October 8 that Actavis planned to approach Allergan for a second time about a potential merger.
Allergan rebuffed Actavis earlier this year, turning down an undisclosed offer that The Wall Street Journal said was likely close to $50 billion.
Allergan, maker of the popular cosmetic drug, Botox, would consider a deal that valued its stock at more than $200 per share, according to sources who spoke with Reuters.
Valeant Makes a Move; Fidelity Takes Sides
As Actavis prepared to re-engage Allergan, its original suitor, Valeant and partner William Ackman, were said to be ready to boost their offer to more than $190 per share, according to another Reuters source.
The latest rumored offer from Valeant would be $15 higher than the company’s previous bid.
Fidelity Investments, the largest shareholder in Actavis, increased its holdings from 3.88 million shares to about 5.88 million shares by the end of August. On October 10 Fidelity said it would be supportive of a merger between Actavis and Allergan.
Dream Team For Hybrid Pharma
Fierce Pharma postulated that Actavis’ desire to become a brand-generics hybrid pharma has led it to a proposed acquisition of Allergan. Allergan, Fierce Pharma suggested, would put the branded drug side of Actavis’ business up front and center.
Chairman Paul Bisaro and his experience on the generic side would complement Saunders to form a management team capable of handling the company’s position as a hybrid giant, according to Fierce Pharma.
Regardless of whether Actavis or Valent ultimately acquires Allergan, Salix may discover that it gets the cold shoulder from its former suitor, Allergan.
At the time of this writing, Jim Probasco had no position in any mentioned securities.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.